Structure-based design of a bromodomain and extraterminal domain (BET) inhibitor selective for the N-terminal bromodomains that retains an anti-inflammatory and antiproliferative phenotype

Christopher R. Wellaway, Paul Bamborough, Sharon G. Bernard, Chun-wa Chung, Peter D. Craggs, Leanne Cutler, Emmanuel H. Demont, John P. Evans, Laurie Gordon, Bhumika Karamshi, Antonia J. Lewis, Matthew J. Lindon, Darren J. Mitchell, Inmaculada Rioja, Peter E. Soden, Simon Taylor, Robert J. Watson, Rob Willis, James M. Woolven, Beata S. WyspiańskaWilliam J. Kerr, Rab K. Prinjha

Research output: Contribution to journalArticle

Abstract

The bromodomain and extraterminal domain (BET) family of epigenetic regulators comprises four proteins (BRD2, BRD3, BRD4, BRDT), each containing tandem bromodomains. To date, small molecule inhibitors of these proteins typically bind all eight bromodomains of the family with similar affinity, resulting in a diverse range of biological effects. To enable further understanding of the broad phenotype characteristic of pan-BET inhibition, the development of inhibitors selective for individual, or sets of, bromodomains within the family is required. In this regard, we report the discovery of a potent probe molecule possessing up to 150-fold selectivity for the N-terminal bromodomains (BD1s) over the C-terminal bromodomains (BD2s) of the BETs. Guided by structural information, a specific amino acid difference between BD1 and BD2 domains was targeted for selective interaction with chemical functionality appended to the previously developed I-BET151 scaffold. Data presented herein demonstrate that selective inhibition of BD1 domains is sufficient to drive anti-inflammatory and antiproliferative effects.
Original languageEnglish
JournalJournal of Medicinal Chemistry
Early online date3 Aug 2020
DOIs
Publication statusE-pub ahead of print - 3 Aug 2020

Keywords

  • assays
  • inhibitors
  • inhibition
  • peptides and proteins
  • selectivity

Fingerprint Dive into the research topics of 'Structure-based design of a bromodomain and extraterminal domain (BET) inhibitor selective for the N-terminal bromodomains that retains an anti-inflammatory and antiproliferative phenotype'. Together they form a unique fingerprint.

  • Cite this

    Wellaway, C. R., Bamborough, P., Bernard, S. G., Chung, C., Craggs, P. D., Cutler, L., Demont, E. H., Evans, J. P., Gordon, L., Karamshi, B., Lewis, A. J., Lindon, M. J., Mitchell, D. J., Rioja, I., Soden, P. E., Taylor, S., Watson, R. J., Willis, R., Woolven, J. M., ... Prinjha, R. K. (2020). Structure-based design of a bromodomain and extraterminal domain (BET) inhibitor selective for the N-terminal bromodomains that retains an anti-inflammatory and antiproliferative phenotype. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.0c00566